| ID | 1142 |
| Name of the vaccine | Pneumovax 23 |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Polysaccharide |
| Nucleic acid content | DNA |
| Age | 2 years and older |
| Description of the vaccine | Pneumococcal vaccine polyvalent (PPSV23). |
| Name of the manufacturer | Merck & Co. |
| Name of the manufacturing country | United States |
| Year of manufacture | 1983 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | Clear, sterile solution |
| Dosage | Single dose of 0.5-mL. |
| Mechanism of action | Enhances opsonization, phagocytosis and killing of pneumococci by leukocytes and other phagocytic cells. |
| Route of administration | Intramuscular |
| Indications | Prevention caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). |
| Export | Distributed by Merck & Co. , USA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Injection-site reactions, headache, asthenia, fatigue and myalgia. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/80547/download |
| Other name | NA |
| Additional Links | NA
|